|
|
|
|
DesonideGenetic Engineering News, Desilux(TM) (desonide) VersaFoam-EF, 0.05%, a low-potency topical steroid formulated to treat atopic dermatitis, is Connetics' first drug candidate seeking a ... Connetics Names David Burch, Regional Sales Director, Ohio and ... Jan 9, 2006 Genetic Engineering News, Foam, 1%. Connetics is developing Velac(R) (a combination of 1% clindamycin and 0.025% tretinoin) Gel, for treating acne; Desilux(TM) (desonide) VersaFoam-EF ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |